Skip to main content
. 2019 Jan 11;14(3):469–481. doi: 10.2215/CJN.08600718

Figure 2.

Figure 2.

Trial-level assessment of the validity of proteinuria as a surrogate end point with the addition of the data from the STOP-IgAN and TESTING trials. (A) With the results of Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy (STOP-IgAN) and Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) added as two separate trials. (B) With the results of TESTING combined with those of other trials of corticosteroids. Circles are the observed treatment effects on the clinical outcome (vertical axis) and change in urine protein (horizontal axis) for each study or study group as for Figure 1. The sizes of the circles are the inverse to the SEM of the treatment effect on the clinical end point, which is related to the number of events of interest. Colors indicate intervention. Red, renin-angiotensin system blockade; yellow, fish oil; green, immunosuppression; dark blue, steroids; light blue, TESTING trial; orange, STOP-IgAN trial. D(dose), Donadio (dose); D(plc), Donadio (placebo); HKVIN, Hong Kong Study Using Valsartan in IgA Nephropathy (43); MMF, mycophenolate mofetil; STOP, STOP-IgAN trial (39); TESTING, TESTING trial (40).